Shraboni Ghosal
Weight Management with Orlistat in Type 2 Diabetes - An Electronic Healthcare Records Study.
Ghosal, Shraboni; Heron, Neil; Mason, Kayleigh; Bailey, James; Jordan, Kelvin
Authors
Neil Heron
Dr Kayleigh Mason k.mason@keele.ac.uk
James Bailey j.bailey4@keele.ac.uk
Kelvin Jordan k.p.jordan@keele.ac.uk
Abstract
Orlistat is recommended as an adjunct to diet and exercise for weight loss in type 2 diabetes mellitus (T2DM). The aims were to explore (i) associations between patient characteristics and orlistat prescribing and to determine (ii) associations of orlistat with weight loss in T2DM/prediabetes. This cohort study used anonymised records of T2DM/prediabetes (2016-2017) patients ≥18 years, from the UK Clinical Practice Research Datalink (CPRD) database. Multivariable logistic regression models determined associations with starting orlistat and stopping it early (<12 weeks of prescriptions) and orlistat's associations with weight loss in those not prescribed 2nd line anti-diabetic medications. Out of 100,552 patients with incident T2DM/prediabetes, 655 (0.8%) T2DM and 128 (0.7%) prediabetes patients were prescribed orlistat. Younger people, females, those in more deprived regions, current smokers, co-prescribed metformin and recorded with hypertension were significantly more likely to be prescribed orlistat while higher baseline HbA1c levels were associated with early stopping. Those who continued orlistat for >12 weeks were more likely to lose ≥5% weight (adjusted OR: 1.69; 95% CI: 1.07, 2.67) than those not on orlistat, but those who stopped orlistat early were less likely (adjusted OR: 0.56; 95% CI: 0.29, 1.09). Orlistat was significantly associated with weight loss in T2DM/prediabetes when taken for at least 12 weeks. However, orlistat is infrequently prescribed and often taken for <12 weeks. Orlistat may be a useful adjunct to lifestyle modifications in T2DM/prediabetes however barriers to continuing orlistat means it may not be effective for everyone in managing weight loss. [Abstract copyright: Copyright © 2024, The Authors.]
Citation
Ghosal, S., Heron, N., Mason, K., Bailey, J., & Jordan, K. (2024). Weight Management with Orlistat in Type 2 Diabetes - An Electronic Healthcare Records Study. British Journal of General Practice (BJGP), BJGP.2023.0684. https://doi.org/10.3399/bjgp.2023.0684
Journal Article Type | Article |
---|---|
Acceptance Date | Apr 9, 2024 |
Online Publication Date | Apr 15, 2024 |
Publication Date | 2024-04 |
Deposit Date | May 8, 2024 |
Publicly Available Date | May 8, 2024 |
Journal | The British journal of general practice : the journal of the Royal College of General Practitioners |
Print ISSN | 0960-1643 |
Publisher | Royal College of General Practitioners |
Peer Reviewed | Peer Reviewed |
Pages | BJGP.2023.0684 |
DOI | https://doi.org/10.3399/bjgp.2023.0684 |
Public URL | https://keele-repository.worktribe.com/output/824103 |
PMID | 38621802 |
Files
BJGP AAM
(382 Kb)
PDF
Licence
https://creativecommons.org/licenses/by/4.0/
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
Copyright Statement
© 2024 The Author(s). This is an Open Access article distributed under the terms of the Creative
Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/). Published by
British Journal of General Practice. For editorial process and policies, see:
https://bjgp.org/authors/bjgp-editorial-process-and-policies
You might also like
Psoriasis and COVID-19: findings from PsoProtectMe.
(2021)
Presentation / Conference
Downloadable Citations
About Keele Repository
Administrator e-mail: research.openaccess@keele.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search